EUCROSS: A European Phase II Trial of Crizotinib in Advanced Adenocarcinoma of the Lung Harboring ROS1 Rearrangements - Preliminary Results

被引：14

作者：

Michels, Sebastian ^{[1
]}

Gardizi, Masyar ^{[1
]}

Schmalz, Petra ^{[2
]}

Thurat, Meike ^{[1
]}

Pereira, Eva ^{[3
]}

Sebastian, Martin ^{[4
]}

Carcereny, Enric ^{[5
]}

Corral, Jesus ^{[6
]}

Paz-Ares, Luis ^{[6
]}

Felip, Enriqueta ^{[7
]}

Grohe, Christian ^{[8
]}

Rodriguez Abreu, Delvys ^{[9
]}

Insa Molla, Amelia ^{[10
]}

Bischoff, Helge ^{[11
]}

Reck, Martin ^{[12
]}

Karachaliou, Niki ^{[13
,14
]}

Scheel, Andreas ^{[15
]}

Brandes, Vanessa ^{[1
]}

Rieke, Fischer ^{[1
]}

Nogova, Lucia ^{[1
]}

Scheffler, Matthias ^{[1
]}

Franklin, Jeremy ^{[16
]}

Hellmich, Martin ^{[16
]}

Massuti, Bartomeu ^{[17
]}

Buettner, Reinhard ^{[15
]}

Rosell, Rafael ^{[18
]}

Wolf, Juergen ^{[1
]}

机构：

[1] Univ Hosp Cologne, Lung Canc Grp Cologne, Cologne, Germany

[2] Clin Trial Ctr Cologne, Cologne, Germany

[3] Spanish Lung Canc Grp, Barcelona, Spain

[4] Univ Klin Frankfurt Main, Frankfurt, Germany

[5] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Med Oncol, Badalona, Spain

[6] Hosp Univ Virgen Del Rocio, Seville, Spain

[7] Vall DHebron Univ Hosp, Barcelona, Spain

[8] Evangel Lungenklin, Berlin, Germany

[9] Univ Hosp Maternoinfantil Canarias, Las Palmas Gran Canaria, Spain

[10] Univ Hosp Clin Valencia, Med Oncol, Valencia, Spain

[11] Thoraxklin Heidelberg, Heidelberg, Germany

[12] Lungclin Grosshansdorf, Grosshansdorf, Germany

[13] Hosp Sagrat Cor, Barcelona, Spain

[14] Germans Trias & Pujol Hlth Sci Inst & Hosp, Barcelona, Spain

[15] Univ Hosp Cologne, Inst Pathol, Cologne, Germany

[16] Univ Hosp Cologne, Inst Med Stat Informat & Epidemiol, Cologne, Germany

[17] Alicante Univ Hosp, Med Oncol, Alicante, Spain

[18] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Barcelona, Spain

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期

关键词：

NSCLC; crizotinib; ros1;

D O I：

10.1016/j.jtho.2016.11.428

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA07.05

引用

页码：S379 / S380

页数：2

共 50 条

[21] Response to crizotinib in a lung adenocarcinoma patient harboring a novel SLC34A2-ROS1 fusion variant
Zhao, Zheng
Song, Zhangjun
Wang, Xuwei
Sun, Haifeng
Yang, Xiaomin
Yuan, Yong
Yu, Pan
ONCOTARGETS AND THERAPY, 2017, 10 : 4129 - 4133
[22] Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSe phase II trial
Moro-Sibilot, D.
Cozic, N.
Pero, M.
Mazieres, J.
Otto, J.
Souquet, P. J.
Bahleda, R.
Wislez, M.
Zalcman, G.
Guibert, S. D.
Barlesi, F.
Mennecier, B.
Monnet, I
Sabatier, R.
Bota, S.
Dubos, C.
Verriele, V.
Haddad, V
Ferretti, G.
Cortot, A.
De Fraipont, F.
Jimenez, M.
Hoog-Labouret, N.
Vassal, G.
ANNALS OF ONCOLOGY, 2019, 30 (12) : 1985 - 1991
[23] Patient harboring a novel PIK3CA point mutation after acquired resistance to crizotinib in an adenocarcinoma with ROS1 rearrangement: A case report and literature review
Xu, Chun-wei
Wang, Wen-xian
Huang, Rong-fang
He, Cheng
Liao, Xing-hui
Zhu, You-cai
Du, Kai-qi
Zhuang, Wu
Chen, Yan-ping
Chen, Gang
Fang, Mei-yu
THORACIC CANCER, 2017, 8 (06) : 714 - 719
[24] Fifty-five months progression-free survival with crizotinib treatment in coexistence of ALK and ROS1 rearrangements in lung adenocarcinoma: an extremely rare case and review of the literature
Korkmaz, Mustafa
Eryilmaz, Melek Karakurt
ANTI-CANCER DRUGS, 2022, 33 (01) : E799 - E801
[25] ROS1 Fusion Chinese Lung Adenocarcinoma Patients Treated with Crizotinib Detected Using Next Generation Genotyping from ctDNA
Niu, Xiaomin
Chen, Zhiwei
Chuai, Shaochuan
Zhou, Zhen
Lu, Shun
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1180 - S1180
[26] Precision Treatment of Advanced Lung Adenocarcinoma With Coexisting EGFR, ALK, and ROS1 Mutations: A Case Report
Zhang, Yaping
Wang, Hui
Wang, Xiaoyan
Li, Shuai
Fang, Hongming
CLINICAL LUNG CANCER, 2021, 22 (05) : E699 - E702
[27] Phase II Trial of Antiemetic Oral Granisetron Plus Dexamethasone for Nausea and Vomiting Caused by Crizotinib in ALK or ROS1 Fusion-Positive NSCLC
Kawasumi, K.
Morise, M.
Kirita, K.
Saeki, K.
Kameoka, H.
Daga, H.
Miyazaki, M.
Toyozawa, R.
Uoi, M.
Harada, M.
Tamaki, S.
Takeda, M.
Fujiwara, K.
Yamanaka, T.
Goto, K.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S851 - S851
[28] Phase I Study of DS-6051b, a ROS1/NTRK Inhibitor, in Japanese Subjects with Advanced Solid Tumors Harboring Either a ROS1 or NTRK Fusion Gene
Nosaki, Kaname
Fujiwara, Yutaka
Takeda, Masayuki
Yamamoto, Noboru
Nakagawa, Kazuhiko
Abe, Chihiro
Shiga, Ryota
Nakamaru, Kenji
Seto, Takashi
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1069 - S1069
[29] Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement
Lim, Sun Min
Kim, Hye Ryun
Lee, Jong-Seok
Lee, Ki Hyeong
Lee, Yun-Gyoo
JooMin, Young
Cho, Eun Kyung
Lee, Sung Sook
Kim, Bong-Seog
Choi, Moon Young
Shim, Hyo Sup
Chung, Jin-Haeng
La Choi, Yoon
Lee, Min Jeong
Kim, Maria
Kim, Joo-Hang
Ali, Siraj M.
Ahn, Myung-Ju
Cho, Byoung Chul
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (23) : 2613 - +
[30] ROS1 fusions in resected stage I-III adenocarcinoma: Results from the European Thoracic Oncology Platform Lungscape project
Speel, Ernst-Jan M.
Dafni, Urania
Thunnissen, Erik
Ruschoff, Jan Hendrik
O'Brien, Cathal
Kowalski, Jacek
Kerr, Keith M.
Bubendorf, Lukas
Sansano, Irene
Joseph, Leena
Kriegsmann, Mark
Navarro, Atilio
Monkhorst, Kim
Madsen, Line Bille
Losa, Javier Hernandez
Biernat, Wojciech
Stenzinger, Albrecht
Ruland, Andrea
Hillen, Lisa M.
Marti, Nesa
Molina-Vila, Miguel A.
Dellaporta, Tereza
Kammler, Roswitha
Peters, Solange
Stahel, Rolf A.
Finn, Stephen P.
Radonic, Teodora
LUNG CANCER, 2024, 194

← 1 2 3 4 5 →